News & Updates
Filter by Specialty:
Most HF patients do not undergo loop diuretic dose reduction after SGLT2i initiation
Majority of the patients with heart failure (HF) who have initiated treatment with sodium-glucose cotransporter 2 inhibitor (SGLT2i) show no change in loop diuretic dose, reports a study.
Most HF patients do not undergo loop diuretic dose reduction after SGLT2i initiation
19 Dec 2023
What prevents patients from receiving a COVID-19 vaccine?
A recent study has found potential associations between vaccine hesitancy and epidemiologic factors, including barriers to receiving vaccination against COVID-19.
What prevents patients from receiving a COVID-19 vaccine?
18 Dec 2023
Second-line CAR-T too costly for treatment of diffuse large B-cell lymphoma
Second-line treatment with axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel) helps improve survival in high-risk patients with diffuse large B-cell lymphoma (DLBCL), but both therapies are expensive, a study has shown.
Second-line CAR-T too costly for treatment of diffuse large B-cell lymphoma
18 Dec 2023
MONARCH 3 final OS data support abemaciclib-NSAI for HR+/HER2- advanced breast cancer
In the final overall survival (OS) analysis of the phase III MONARCH 3 trial, the combination of the CDK 4/6 inhibitor abemaciclib and a nonsteroidal aromatase inhibitor (NSAI) continued to show clinically meaningful signals as first-line (1L) treatment for HR+/HER2- advanced breast cancer.
